Multiple myeloma -GT919

On December 20, 2022, the molecular glue degrader GT919 developed by Gluetacs was approved by Center for Drug Evaluation, NMPA to enter phase I clinical trial. On July 24, 2023, GT919 was announced dosing of the first patient in the phase I clinical trial. On March 12, 2024, it was approved to carry out phase I clinical trial of combining with dexamethasone.
Recruitment criteria:

You may be selected for this study if you meet the following key criteria:

  1. Male or female, over 18 years old;
  2. Patients diagnosed with relapsed or refractory multiple myeloma (rrMM);
  3. ECOG score physical status <2, expected survival >12 weeks;
  4. Have adequate organ function, including blood system, liver function, kidney function, coagulation function, etc.;
  5. Subjects of reproductive age should agree to use effective contraception from the date of signing the informed consent 6 months after the last dosing.

    Medical Center:

    The First Affiliated Hospital of Soochow University (Director Fu Zhengzheng)
    Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School (Director Chen Bing)
    Henan Cancer Hospital (Director Yin Qingsong)